Document Detail


Deterioration of blood pressure control after discontinuation of a physician-pharmacist collaborative intervention.
MedLine Citation:
PMID:  20180606     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
STUDY OBJECTIVE: To assess blood pressure control after discontinuation of a physician-pharmacist collaborative intervention.
DESIGN: Comparative analysis of data of the patients who received the intervention versus a control group from a prospective, cluster-randomized, 9-month efficacy trial and the same patients' data 18 and 27 months after completion of the trial, abstracted from their medical records.
SETTING: Five primary care medical offices operated by a university health system.
PATIENTS: One hundred four patients with hypertension; 65 were in the intervention group, and 39 were in the control group.
MEASUREMENTS AND MAIN RESULTS: In the prospective study, patients were randomized to receive a physician-pharmacist collaborative intervention to improve blood pressure control or to the control group. Systolic and diastolic blood pressures were measured by a research nurse at baseline and at the end of the study (9 mo later). In the current study, data were abstracted for blood pressure and blood pressure control at 18 and 27 months (9 and 18 mo, respectively, after discontinuation of the study). At baseline, mean +/- SD systolic blood pressure was 152.5 +/- 9.5 and 150.1 +/- 9.6 mm Hg in the intervention and control groups, respectively (p=0.22). At 9 months, systolic blood pressure decreased to 124.5 +/- 10.7 and 132.0 +/- 15.1 mm Hg (p=0.0038 between groups), and blood pressure was controlled in 78.5% and 48.7% (p=0.0017) of patients in the intervention and control groups, respectively. By 18 months, systolic blood pressure had deteriorated to 131.0 +/- 12.2 and 143.3 +/- 17.5 mm Hg (p<0.001), and blood pressure control rates decreased to 53.9% and 30.8% (p=0.02). By 27 months, systolic blood pressure was 131.3 +/- 13.0 and 141.2 +/- 15.8 mm Hg (p=0.0008), and blood pressure control was 55.4% and 35.9% (p=0.05).
CONCLUSION: A sustained positive effect on blood pressure control was noted up to 18 months after discontinuation of a physician-pharmacist collaborative intervention, when compared with a control group. Blood pressure control did deteriorate at a similar rate in both the intervention and control groups, but the percentage of patients with controlled blood pressure remained significantly higher in the intervention group. These results suggest that continued interventions by pharmacists may be necessary to maintain high rates of blood pressure control, especially in those patients whose blood pressure begins to increase.
Authors:
Barry L Carter; William R Doucette; Carrie L Franciscus; Gail Ardery; Karen M Kluesner; Elizabeth A Chrischilles
Related Documents :
3278976 - Labetalol blunts morning pressor surge in systolic hypertension.
2892866 - Labetalol in the treatment of hypertension in elderly and younger patients.
12243636 - Effects of losartan on cardiovascular morbidity and mortality in patients with isolated...
19996066 - Outcomes among hypertensive patients with concomitant peripheral and coronary artery di...
12359976 - Variable day/night bias in 24-h non-invasive finger pressure against intrabrachial arte...
6830016 - Equine esophageal pressure profile.
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Pharmacotherapy     Volume:  30     ISSN:  1875-9114     ISO Abbreviation:  Pharmacotherapy     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-02-25     Completed Date:  2010-05-25     Revised Date:  2014-05-28    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  228-35     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antihypertensive Agents / administration & dosage,  therapeutic use*
Blood Pressure / drug effects*
Female
Follow-Up Studies
Humans
Hypertension / prevention & control*
Interprofessional Relations
Male
Medical Records
Medication Adherence
Middle Aged
Pharmaceutical Services*
Pharmacists
Physicians
Practice Guidelines as Topic
United States
Young Adult
Grant Support
ID/Acronym/Agency:
5U18HSO16094//PHS HHS; R01 HL069801/HL/NHLBI NIH HHS; R01 HL069801-03/HL/NHLBI NIH HHS; R01 HL69801/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Antihypertensive Agents
Comments/Corrections
Comment In:
Pharmacotherapy. 2010 Mar;30(3):221-3   [PMID:  20180604 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Smectic Foams.
Next Document:  Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.